GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (WAR:SPH) » Definitions » Cash Flow from Operations

Sopharma AD-Sofia (WAR:SPH) Cash Flow from Operations : zł104 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sopharma AD-Sofia Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Jun. 2024, Sopharma AD-Sofia's Cash Receipts from Operating Activities was zł1,259 Mil. Its Cash Payments was zł-873 Mil. Its Dividends Paid was zł0 Mil. Its Dividends Received was zł0 Mil. Its Interest Paid was zł-6 Mil. Its Interest Received was zł0 Mil. Its Taxes Refund Paid was zł-43 Mil. And its Cash Flow from Others was zł0 Mil. In all, Sopharma AD-Sofia's Cash Flow from Operations for the three months ended in Jun. 2024 was zł336 Mil.


Sopharma AD-Sofia Cash Flow from Operations Historical Data

The historical data trend for Sopharma AD-Sofia's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma AD-Sofia Cash Flow from Operations Chart

Sopharma AD-Sofia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -280.21 -391.40 -165.72 240.15 98.24

Sopharma AD-Sofia Quarterly Data
Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.48 -142.33 252.32 -341.88 336.32

Sopharma AD-Sofia Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Sopharma AD-Sofia's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Sopharma AD-Sofia's Cash Flow from Operations for the quarter that ended in Jun. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł104 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sopharma AD-Sofia  (WAR:SPH) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Sopharma AD-Sofia's cash receipts from operating activities for the three months ended in Jun. 2024 was zł1,259 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Sopharma AD-Sofia's cash payments for the three months ended in Jun. 2024 was zł-873 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Sopharma AD-Sofia's cash payments for the three months ended in Jun. 2024 was zł0 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Sopharma AD-Sofia's cash payments for the three months ended in Jun. 2024 was zł0 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Sopharma AD-Sofia's cash payments for the three months ended in Jun. 2024 was zł-6 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Sopharma AD-Sofia's cash payments for the three months ended in Jun. 2024 was zł0 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Sopharma AD-Sofia's cash payments for the three months ended in Jun. 2024 was zł-43 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Sopharma AD-Sofia's cash flow from others for the three months ended in Jun. 2024 was zł0 Mil.


Sopharma AD-Sofia Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Sopharma AD-Sofia Business Description

Traded in Other Exchanges
Address
5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.